Dr. Shannon N. Westin, MD, MPH
Associate Professor
Director, Early Drug Development and Phase I Trials
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas, MD Anderson Cancer Center

Dr. Westin received her doctorate of Medicine from the University of Florida College of Medicine.  She completed Obstetrics and Gynecology residency at the University of North Carolina – Chapel Hill and fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.  During fellowship, she received an MPH with a concentration in epidemiology from the University of Texas, School of Public Health. In addition to her training in Gynecologic Oncology, she also completed a short fellowship in Investigational Cancer Therapeutics.  She joined the faculty at The University of Texas MD Anderson Cancer Center in 2010. She has been honored as a K12 scholar, Andrew Sabin Family Fellow, and a Gynecologic Oncology Group (GOG) Foundation Scholar Investigator.

Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. Dr. Westin is a member of the NRG Oncology – GOG Developmental Therapeutics, Phase I, and Early Phase Protocol Oversight committees.  She is the co-PI for five major projects in her institution’s SPORE in Uterine Cancer and SPORE in Ovarian Cancer.  In addition, she is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies.

Dr. Westin has authored or co-authored greater than 150 scientific publications, book chapters and invited articles. She has been invited to lecture as an expert on clinical trials, genomic testing and targeted therapy in gynecologic malignancies in national and international venues. She was selected for the competitive American Society of Clinical Oncology (ASCO) Leadership Development program and serves on five ASCO committees including the Communications Committee and Gynecologic Cancer Guidelines Group. She currently serves on the Board of Directors for the Society of Gynecologic Oncology (SGO) and the GOG Foundation.  In addition to serving on the National Cancer Institute (NCI) Uterine Task Force and Gynecologic Cancer Steering Committee (GCSC), she serves as a co-chair of the GCSC Ovarian Cancer Task Force and the NCI Ovarian Cancer Clinical Trials Planning Meeting. As such, she is guiding development of future NCI trials designed to push the field forward and expand the role of precision medicine in ovarian cancer.

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Authors/Presenters:
Ursula Matulonis, MD–has disclosed that she is a consultant for AstraZeneca, Merck, NextCure, and Novartis. He receives financial or material support from DSMB and Symphogen. 

Angeles Alvarez Secord, MD– has disclosed that she receives grant/research supports from AbbVie, AstraZeneca, Clovis, Merck, and Oncoquest. 

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Shannon N. Westin, MD, MPH–has disclosed that she is a consultant for AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis. She receives grant/research support from AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis.

Content Reviewer: 
Justine Cooper Pickarski - has no relevant financial relationships to disclose in relation to the content of this activity.